The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs
Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...
Cibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)
Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the fourth quarter, ...
Kalkine Media4d
How Is Avidity Biosciences Inc. (NASDAQ:RNA) Positioned in the Biotech Sector?
Highlights,Swiss National Bank expanded its holdings in Avidity Biosciences Inc. during the fourth quarter.,Multiple ...
Investing5d
Avidity Biosciences Inc (RNA)
Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Utilities, Consumer Goods and Consumer ...
Morningstar2d
Avidity Biosciences Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioSpace2d
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Investors Chronicle1d
The stars are aligning for this savvy biotech trust
Drug development is coming back in vogue and this fund’s ‘full life cycle’ approach means it’s ready to capture the gains ...
pharmaphorum6d
Buoyed by muscular dystrophy data, Avidity raises $345m
Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an impressive ...
Zacks Investment Research on MSN4d
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...